Julia Krzykalla

May 12, 2023 | thelancet.com | Hartmut Döhner |Daniela Weber |Julia Krzykalla |Walter Fiedler

Background Acute myeloid leukaemia with mutated NPM1 is associated with high CD33 expression and intermediate-risk cytogenetics. The aim of this study was to evaluate intensive chemotherapy with or without the anti-CD33 antibody–drug conjugate gemtuzumab ozogamicin in participants with newly diagnosed, NPM1-mutated acute myeloid leukaemia. Methods This open-label, phase 3 trial was conducted at 56 hospitals in Germany and Austria.